<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of pulmonary sarcoidosis: Initial approach</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of pulmonary sarcoidosis: Initial approach</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of pulmonary sarcoidosis: Initial approach</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel A Culver, DO, FCCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sarcoidosis is a multisystem disease of unknown etiology characterized by tissue infiltration with noncaseating granulomas. The granulomas may occur in any organ, but the most frequently affected sites are the lungs, lymph nodes, skin, eyes, and liver. Patients with pulmonary sarcoidosis are often asymptomatic at presentation. When symptomatic, patients usually report dyspnea, cough, or nonspecific chest discomfort. Most patients with pulmonary sarcoidosis do not require treatment because they either have asymptomatic, nonprogressive disease or experience spontaneous remission. Progressive lung disease occurs in approximately 25 percent and disabling organ failure in up to 10 percent of cases [<a href="#rid1">1-4</a>]. Sarcoidosis patients referred to tertiary centers are more likely to have risk factors associated with the need for systemic treatment [<a href="#rid5">5</a>].</p><p>This extreme heterogeneity of disease activity and long-term outcomes leads to several challenges in disease management, which are only further enhanced by common adverse side effects of immunomodulatory therapy. The key questions regarding the initial treatment of sarcoidosis are the following:</p><p class="bulletIndent1"><span class="glyph">●</span>What are the indications for treatment?</p><p class="bulletIndent1"><span class="glyph">●</span>What is the initial treatment approach?</p><p class="bulletIndent1"><span class="glyph">●</span>What is the optimal duration of therapy?</p><p class="bulletIndent1"><span class="glyph">●</span>How should the disease course and the response to therapy be monitored?</p><p class="bulletIndent1"><span class="glyph">●</span>Does treatment alter the course of pulmonary sarcoidosis?</p><p></p><p>There are few randomized, placebo-controlled clinical trials specifically for sarcoidosis. Consequently, much of the ensuing discussion is based on our practical experience treating patients with this condition.</p><p>An overview of the initial treatment of sarcoidosis will be presented here. The clinical manifestations and diagnostic evaluation of sarcoidosis and treatment of refractory pulmonary sarcoidosis are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p></p><p>Severe extrapulmonary involvement, particularly of the heart, eyes, kidney, or neurologic system, can also necessitate initiation of systemic therapy. First-line treatment of cutaneous disease frequently involves topical and intralesional therapy rather than systemic agents, which are reserved for extensive, rapidly progressive, or disfiguring disease. The treatment of extrapulmonary sarcoidosis is discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/113686.html" rel="external">"Management and prognosis of cardiac sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4317.html" rel="external">"Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13773.html" rel="external">"Cutaneous sarcoidosis: Management"</a>.)</p><p></p><p class="headingAnchor" id="H3907774300"><span class="h1">ASSESSING DISEASE SEVERITY AND PROGRESSION</span><span class="headingEndMark"> — </span>For patients with more severe or progressing lung disease, treatment with immunomodulatory therapy may improve symptoms, decrease radiographic disease burden, and can prevent disease progression [<a href="#rid6">6-8</a>]. Oral immunosuppression is therefore most appropriate for patients with pulmonary sarcoidosis at moderate to high risk of disease progression and/or significantly impaired quality of life due to pulmonary symptoms [<a href="#rid6">6</a>].</p><p>Objective high-risk features, for which treatment is commonly administered, include [<a href="#rid9">9,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV radiographic disease  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>), particularly progressive moderate to severe pulmonary fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Substantially reduced forced vital capacity (FVC), forced expiratory volume in one second (FEV<sub>1</sub>), and diffusing capacity of the lung for carbon monoxide (DLCO)</p><p class="bulletIndent1"><span class="glyph">●</span>Significantly reduced exercise tolerance in individuals with parenchymal lung involvement</p><p></p><p>When three or more organs are involved in the disease (multisystem involvement), or when extrapulmonary manifestations affect the skin, bones, or joints (excluding erythema nodosum), the risk of a more severe or prolonged disease course increases [<a href="#rid9">9,11-15</a>]. In some cases, the extent of disease across multiple organ systems may indicate potential benefits from treatment, even if individual systems do not meet the threshold for initiating therapy.</p><p>There are no well-defined criteria for determining changes in pulmonary function that indicate disease progression [<a href="#rid16">16</a>]. In practice, progression is identified by changes in testing that are unlikely to be due to random variation, particularly when accompanied by worsening symptoms. The decision to initiate or escalate therapy should be made cautiously, considering higher thresholds in such cases. Some markers that may prompt clinicians to consider starting or intensifying therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary symptoms leading to a clinically relevant impairment in quality of life (ie, when the burden of the symptoms outweighs the risks of therapy in a patient-centered decision-making process)</p><p class="bulletIndent1"><span class="glyph">●</span>A decline in pulmonary function testing that is not likely to represent testing variability</p><p class="bulletIndent1"><span class="glyph">●</span>A decrease in oxygen saturation on pulse oximetry of ≥4 percent at rest or with exercise (indicating worsening gas exchange)</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive worsening of interstitial opacities</p><p></p><p>Nonimaging markers of disease progression typically lead to the use of cross-sectional imaging to evaluate changes in the extent of lung tissue and lymph node involvement over time. This helps to rule out other potential causes and establish a new baseline before starting treatment. However, if radiographic changes or spirometry are disproportionately preserved despite low DLCO or oxygen saturation, further investigation for pulmonary hypertension is necessary. Diagnosing and treating pulmonary hypertension requires a more comprehensive diagnostic and treatment strategy. (See  <a class="medical medical_review" href="/d/html/132051.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Diagnostic evaluation in adults"</a> and  <a class="medical medical_review" href="/d/html/138414.html" rel="external">"Sarcoidosis-associated pulmonary hypertension: Treatment and prognosis in adults"</a>.)</p><p class="headingAnchor" id="H3923662352"><span class="h1">APPROACH TO ASYMPTOMATIC PATIENTS</span><span class="headingEndMark"> — </span>Most patients with asymptomatic pulmonary sarcoidosis have low risk of disease progression and do not require treatment  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). In the absence of symptoms, sarcoidosis burden is assessed by pulmonary function testing and radiographic staging  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to most asymptomatic patients</strong> – We do not treat asymptomatic patients with stage I to III disease or nodular sarcoidosis unless there are significant abnormalities in pulmonary function and evidence of progression. A large majority of asymptomatic patients with stage I disease and nodular sarcoidosis will have spontaneous remission, while patients with stage II and III disease have a more variable disease course [<a href="#rid17">17-19</a>]. (See <a class="local">'Long-term outcome'</a> below.)</p><p></p><p class="bulletIndent1">The appropriate course of action for untreated asymptomatic patients is unknown. To monitor their condition, we recommend follow-up visits at intervals of three to six months during the first year and every six to twelve months thereafter. During these visits, we evaluate the presence of symptoms and perform spirometry as well as diffusing capacity of the lung for carbon monoxide (DLCO). We obtain a repeat chest radiograph after the initial six months followed by annual radiographs for at least two to three years to assess stability. If the chest radiographs and other tests do not provide sufficient information for confident decision-making, we may conduct cross-sectional imaging using noncontrast high-resolution computed tomography (chest CT).</p><p></p><p class="bulletIndent1">There are limited data supporting the use of chest CT scans as the primary factor for making prognosis or treatment decisions, unless there is a deterioration in symptoms or changes in pulmonary function testing (PFTs). If there is evidence of progressive disease, it is advisable to consider immunomodulatory therapy. (See <a class="local">'Assessing disease severity and progression'</a> above and <a class="local">'Patients with more severe or progressive disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients with advanced radiographic disease</strong> – A small subset of asymptomatic patients who are at high risk of developing pulmonary disability due to disease progression may potentially benefit from early treatment [<a href="#rid6">6,17</a>]. In certain cases, we provide a short trial of treatment for asymptomatic or minimally symptomatic patients with stage IV radiographic disease  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>). Additionally, patients with significant abnormalities in PFTs may also be considered for a trial of treatment to evaluate the potential for reversibility.</p><p></p><p class="bulletIndent1">The details of treatment for these patients with severe disease are discussed below. (See <a class="local">'Patients with more severe or progressive disease'</a> below.)</p><p></p><p class="headingAnchor" id="H3084320120"><span class="h1">SYMPTOMATIC PATIENTS WITH MILD LUNG INVOLVEMENT</span></p><p class="headingAnchor" id="H3850512492"><span class="h2">Common symptoms and their evaluation</span><span class="headingEndMark"> — </span>Most patients with stage I to II radiographic changes  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>) and minimal or mild pulmonary function abnormalities  (<a class="graphic graphic_algorithm graphicRef139645" href="/d/graphic/139645.html" rel="external">algorithm 2</a>) are asymptomatic. For those with symptoms, careful evaluation for alternative explanations is appropriate.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cough</strong> – For patients with cough, we first strongly encourage cessation of smoking and vaping. We then assess for common potential causes of chronic cough, including asthma, postinfectious cough, upper airway cough syndrome, angiotensin-converting enzyme (ACE) inhibitor therapy, and reflux disorders. (See  <a class="medical medical_review" href="/d/html/1460.html" rel="external">"Causes and epidemiology of subacute and chronic cough in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest pain</strong> – Nonexertional chest pain (chest pain that arises spontaneously, at rest, or during activities that do not involve strenuous exercise) is common in sarcoidosis and can be a significant cause of impaired quality of life. Its relationship to discrete entities, such as pulmonary hypertension, cardiac sarcoidosis, or lymphadenopathy, is uncertain. For patients with exertional chest discomfort, we typically evaluate patients for causes of the pain unrelated to sarcoidosis, such as coronary artery disease, along with assessing for cardiac involvement. In cases where the chest pain is related to cardiac sarcoidosis, specific treatments may be necessary. If the chest pain is due to inflammation or granulomas in the chest wall, anti-inflammatory medications or, occasionally, corticosteroids may be prescribed. Pain management strategies including analgesics or nonsteroidal anti-inflammatory drugs (NSAIDs) are often helpful to alleviate the discomfort. (See  <a class="medical medical_review" href="/d/html/6832.html" rel="external">"Outpatient evaluation of the adult with chest pain", section on 'Evaluation for stable myocardial ischemia'</a> and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asthma</strong> – Distinguishing sarcoidosis with airway involvement from asthma can be difficult, as both can result in ventilatory obstruction with bronchodilator responsiveness. Both may also exhibit positive bronchoprovocation testing. A history of childhood asthma, peripheral eosinophilia, or elevated fraction of exhaled nitric oxide (FeNO) increases the likelihood of asthma compared with granulomatous airway inflammation. Often, the distinction is clinically meaningless, as both asthma and airway-centered sarcoidosis may respond well to inhaled therapies. In rare instances, endobronchial biopsy may be helpful to distinguish the two.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fatigue</strong> – Fatigue is common (reported in 50 to 90 percent of patients) and may be a disabling symptom in sarcoidosis with a significant impact on quality of life [<a href="#rid20">20-23</a>]. Treating and controlling sarcoidosis itself is often important in addressing fatigue. Managing symptoms such as pain, sleep disturbances, or depression can help alleviate fatigue. Adopting healthy lifestyle and learning to manage energy levels and prioritize tasks can help in coping with fatigue. Seeking psychologic support through counseling, support groups, or therapy can also provide tools and strategies to manage fatigue-related distress.</p><p></p><p class="headingAnchor" id="H3063437728"><span class="h2">Low-dose oral glucocorticoid therapy</span><span class="headingEndMark"> — </span>For patients with minimal or mild radiographic and pulmonary function changes, but impaired quality of life due to pulmonary symptoms, a therapeutic trial of low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> may be appropriate  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). Since these patients have a 50 to 80 percent chance of spontaneous remission [<a href="#rid19">19,24</a>] despite their bothersome symptoms, it is appropriate to engage in shared decision-making around the potential benefits and risks of low-dose glucocorticoid therapy. We closely monitor patients at increased risk for adverse effects from glucocorticoid therapy (eg, patients with type 2 diabetes, osteoporosis, obesity, or history of psychosis).</p><p>This therapeutic approach is consistent with recommendations by the European Respiratory Society Guideline on the treatment of sarcoidosis [<a href="#rid6">6</a>] and is based on indirect and older evidence from randomized trials that treatment with even low doses of oral glucocorticoids increases the rate of early radiographic improvement [<a href="#rid7">7,25</a>]. We typically initiate therapy at moderate doses (eg, 20 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) to assess responsiveness, followed by a more rapid taper towards low-dose therapy (5 to 10 mg daily) over a few weeks after initial improvement.</p><p>Most responses to therapy can be observed within four weeks, even with lower doses of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Duration of therapy should be based on degree of response balanced against any adverse effects of glucocorticoid therapy. In our experience, most patients with good response can undergo slow tapering to the minimal effective dose starting after four weeks of treatment. The timing and aggressiveness of trials of tapering should include several factors, in discussion with the patient [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Severity of pulmonary disease (radiographic features, pulmonary function tests [PFTs])</p><p class="bulletIndent1"><span class="glyph">●</span>Chronicity</p><p class="bulletIndent1"><span class="glyph">●</span>Results of prior tapering attempts</p><p class="bulletIndent1"><span class="glyph">●</span>Initial difficulty obtaining control of disease</p><p class="bulletIndent1"><span class="glyph">●</span>Tolerability of the immunosuppressive regimen</p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of active granulomatous inflammation (eg, positron emission tomography, when available)</p><p></p><p class="headingAnchor" id="H226431888"><span class="h2">Inhaled glucocorticoid therapy (alternative)</span><span class="headingEndMark"> — </span>Inhaled glucocorticoids have been evaluated for the treatment of mild or asymptomatic pulmonary sarcoidosis, but results are conflicting [<a href="#rid7">7,27-37</a>]. In our experience, they are most likely to be effective for symptomatic treatment of cough or airways hyperreactivity  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>).</p><p><a class="drug drug_general" data-topicid="9167" href="/d/drug information/9167.html" rel="external">Budesonide</a> (800 to 1600 mcg twice daily) and <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> (500 to 1000 mcg twice daily) have been the most frequently studied [<a href="#rid7">7,29,34-37</a>]. These high doses  (<a class="graphic graphic_table graphicRef78011" href="/d/graphic/78011.html" rel="external">table 2</a>) result in significant systemic absorption (similar to low-dose oral administration) and higher risks of side effects. Coadministration of medications that inhibit cytochrome p450 3A4 (CYP450 3A4) impairs metabolism of budesonide and fluticasone and may cause additional systemic buildup  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids"</a>.)</p><p>Patients who do not respond after four to six weeks should discontinue therapy and engage in shared decision-making regarding observation versus initiation of low-dose oral glucocorticoids. (See <a class="local">'Low-dose oral glucocorticoid therapy'</a> above.)</p><p>In trials and retrospective studies, inhaled glucocorticoids appear to modulate the alveolitis of sarcoidosis [<a href="#rid33">33,34</a>] and provide clinical benefit in some subjects, but they do not lead to consistent improvements in lung function [<a href="#rid7">7,30,31,35,37</a>]. As an example, one randomized trial of 2000 mcg/day of <a class="drug drug_general" data-topicid="8951" href="/d/drug information/8951.html" rel="external">fluticasone</a> in 44 patients found no significant differences in lung function but borderline improvements in cough, breathlessness, wheeze, and general health perception [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2804261813"><span class="h2">Recurrence of symptoms during tapering</span><span class="headingEndMark"> — </span>If there are recurrent symptoms without other radiographic or physiologic changes during tapering of oral or inhaled glucocorticoids, therapy may be resumed at the last effective dose. If this dose is ineffective or if there is recurrence of symptoms alone after stopping therapy, resumption of the initial dosing for symptom management is appropriate.</p><p>For patients who have an exacerbation or a relapse that includes radiographic progression or worsening of pulmonary function, we initiate treatment for progressive disease. (See <a class="local">'Patients with more severe or progressive disease'</a> below and <a class="local">'Relapses and acute bronchitic symptoms'</a> below.)</p><p class="headingAnchor" id="H2120563740"><span class="h1">PATIENTS WITH MORE SEVERE OR PROGRESSIVE DISEASE</span><span class="headingEndMark"> — </span>The mainstay of initial treatment for patients with severe or progressive pulmonary sarcoidosis is glucocorticoid therapy, which is generally effective at attenuating the granulomatous inflammatory process. Optimal management of glucocorticoids improves disease while minimizing adverse medication effects. Most patients with these pulmonary manifestations are likely to require longer term therapy, so glucocorticoid-sparing adjuncts (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>) should be considered as part of the therapeutic plan and discussed early in the treatment course.</p><p class="headingAnchor" id="H1290468746"><span class="h2">Goals of oral glucocorticoid treatment</span><span class="headingEndMark"> — </span>The goals of titrated glucocorticoid therapy are to reduce disease burden and prevent the development of irreversible end-organ damage (eg, fibrotic lung disease) while also minimizing adverse side effects and comorbidities. We achieve these goals by using higher upfront doses for stabilization and/or regression of active disease followed by identification of a lower longer-term dose that maintains clinical stability. We typically attempt to taper off glucocorticoids after one year or several months of disease quiescence on maintenance therapy (whichever comes later).</p><p>Oral glucocorticoids have been used for decades as the primary agents for the relief of symptoms and control of potentially disabling respiratory impairment from pulmonary sarcoidosis, even if they do not cure the disease [<a href="#rid1">1,38-40</a>]. The optimal use of glucocorticoid therapy is not known, so choosing a dose requires balancing the likelihood of response against the risk of adverse effects [<a href="#rid2">2,3,28,41</a>]. The few trials in this area involve mixed populations of patients, most of whom are not at highest risk, so extrapolation of best practice from the available data is difficult. The approach outlined below is therefore based primarily on expert opinion. (See <a class="local">'Initial and maintenance dosing'</a> below and <a class="local">'Stopping glucocorticoid therapy'</a> below.)</p><p class="headingAnchor" id="H213698715"><span class="h2">Initial and maintenance dosing</span><span class="headingEndMark"> — </span>For all patients who demonstrate progressive or bothersome pulmonary disease, we suggest initial therapy with oral glucocorticoids rather than observation alone  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). For some patients at higher risk for steroid toxicities, initial therapy with steroid-sparing agents may be appropriate. Prior to initiating therapy, we assess patients for comorbid noninflammatory conditions that might contribute to pulmonary symptoms (eg, heart failure, pulmonary hypertension, obesity) [<a href="#rid39">39</a>] as well as for infectious diseases that could worsen with immunomodulatory agents (eg, tuberculosis, strongyloidiasis).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial dose</strong> – We begin therapy with oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at a daily dose of 20 to 30 mg/day; 20 mg is sufficient for most patients [<a href="#rid2">2,40,42,43</a>]. This dosing is generally effective and may have lower risks of adverse side effects than higher initial ranges.</p><p></p><p class="bulletIndent1">The best data to support this approach are from an open-label trial of 86 patients comparing initiation of sarcoidosis treatment with 20 versus 40 mg of <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> daily (followed by a protocolized six-month taper) [<a href="#rid43">43</a>]. The majority (81 percent) of the patients were initiated on therapy for pulmonary indications. All participants demonstrated improvement in or stabilization of symptoms by eight weeks after treatment initiation, with similar outcomes in both groups. Following six months of treatment, the incidence of treatment failure was likewise similar (14 percent in the 40 mg daily group and 9 percent in the 20 mg daily group), as were rates of subsequent relapse (34 and 35 percent in the higher- and lower-dose groups, respectively). Adverse effects of systemic glucocorticoids were very common and not statistically different (100 percent in the 40 mg group and 88 percent in the 20 mg group over six months of therapy).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring initial response</strong> – We reassess patients four to six weeks after starting therapy. If symptoms, radiographic abnormalities, and pulmonary function testing (eg, spirometry, diffusing capacity of the lung for carbon monoxide [DLCO], ambulatory oximetry) are improved, the initial dose is tapered. (See <a class="local">'Assessing response to therapy'</a> below.)</p><p></p><p class="bulletIndent1">If the clinical and physiologic parameters are unimproved (but not worsened) after four to six weeks at the initial dose, we continue that dose an additional four to six weeks. However, most improvement with glucocorticoids is typically apparent in three to four weeks' time [<a href="#rid3">3,44</a>]. Delayed improvement or stabilization of previously progressing disease still merits attempted tapering, but lack of response or worsening disease should prompt reevaluation of the diagnosis followed by treatment with alternative immunosuppressants for refractory disease. (See <a class="local">'Approach in patients with suboptimal response'</a> below and  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance phase</strong> – Tapering schedules for glucocorticoid therapy can vary, especially when considering the presence of adverse side effects from the medication. A common approach involves initially decreasing the dose more rapidly (eg, with 5 to 10 mg decrements of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>), but then reducing the magnitude of the dose reduction (&lt;5 mg decrements) to achieve a slower taper before complete discontinuation. Our experience suggests that individuals who have been on glucocorticoids for a relatively longer duration tend to have better outcomes with slower tapering schedules, particularly when the dose is reduced to 10 mg or less of prednisone.</p><p></p><p class="bulletIndent1">It is important to distinguish glucocorticoid withdrawal symptoms from adrenal insufficiency. Withdrawal symptoms, such as fatigue and arthralgias, may occur whenever the dose is tapered too quickly regardless of the starting dose. In general, steroid withdrawal symptoms can be treated with a slower taper and reassurance. Adrenal insufficiency occurs only at doses less than 7.5 mg/day; distinguishing it from steroid withdrawal symptoms may require biochemical testing. (See  <a class="medical medical_review" href="/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults"</a>.)</p><p></p><p class="bulletIndent1">The ideal maintenance range for control of pulmonary sarcoidosis is individualized, and it must be identified practically. Historically, 10 to 15 mg/day of oral <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> was deemed acceptable [<a href="#rid2">2,7,8,25,45,46</a>], but in our experience, a large proportion of patients can be adequately maintained on lower doses, sometimes even less than 5 mg/day. In chronic treatment, it is not clear that any dose of prednisone is a "safe" dose with no risk for long term steroid toxicities [<a href="#rid47">47</a>]. Alternate day therapy with prednisone has also been used for maintenance after initial daily therapy as an attempt to reduce the risk of adverse effects from the glucocorticoids, but few data are available to support its efficacy. Likely, the benefits and adverse effects are comparable to similar total dosing on a daily schedule [<a href="#rid48">48</a>]. During the maintenance phase, we reassess the patient at three- to six-month intervals for evidence of disease worsening (relapses) or development of glucocorticoid-related adverse effects. (See <a class="local">'Assessing response to therapy'</a> below and <a class="local">'Relapses and acute bronchitic symptoms'</a> below and <a class="local">'Adverse effects'</a> below.)</p><p></p><p class="bulletIndent1">Recurrence of symptoms, such as cough, dyspnea, and wheezing, upon early treatment withdrawal is common (occurring in approximately 60 percent of patients), so we continue the maintenance dose for at least three to six months, giving a total treatment period of at least a year. A brief course of higher doses (eg, 20 mg/day given for two weeks) is sometimes required to relieve an episode of bronchitic symptoms. (See <a class="local">'Relapses and acute bronchitic symptoms'</a> below.)</p><p></p><p class="headingAnchor" id="H268663755"><span class="h2">Approach in patients with suboptimal response</span><span class="headingEndMark"> — </span>While most patients respond well to oral glucocorticoid therapy, there are several common scenarios where continued management with glucocorticoids is suboptimal:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who do not respond or clinically worsen despite an adequate trial of initial therapy (eg, the equivalent of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg/day for at least one to two months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who require ongoing long-term maintenance (more than six months) with <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, especially those in whom higher maintenance doses are needed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who become intolerant of maintenance glucocorticoids over time due to hyperglycemia, excessive weight gain, myopathy, or severe osteoporosis</p><p></p><p>These patients typically require alternative immunosuppressive agents (eg, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>, or tumor necrosis factor inhibitors), sometimes in addition to lower-dose glucocorticoids. Referral to a sarcoidosis center may be prudent in this setting. The management of pulmonary sarcoidosis refractory to initial management is described separately. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p class="headingAnchor" id="H878746291"><span class="h2">Stopping glucocorticoid therapy</span><span class="headingEndMark"> — </span>Although the proper length of therapy in patients who respond to treatment is unknown, we usually aim for approximately one year of therapy for this group [<a href="#rid12">12,13,38</a>]. Many patients can discontinue systemic glucocorticoids after approximately a year of treatment [<a href="#rid49">49</a>]. Regardless of a robust response, therapy should be given for at least three to six months to be effective and to reduce the likelihood of relapse. Relapses requiring another course of therapy are frequent following reduction or withdrawal of glucocorticoids, ranging from 14 to 74 percent among those with disease of recent onset (≤5 years) [<a href="#rid3">3</a>]. A small number of patients require more long-term or indefinite maintenance therapy to control their symptoms [<a href="#rid50">50</a>].</p><p>Tapering is appropriate in patients with initial improvement and clinical stability (or continued improvement) throughout the maintenance phase of treatment. We typically use the following <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> tapering regimens:</p><p class="bulletIndent1"><span class="glyph">●</span>2.5 to 5 mg/day every three to four weeks at <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> doses between 20 and 10 mg/day.</p><p class="bulletIndent1"><span class="glyph">●</span>2.5 mg/day every three to four weeks at <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> doses between 10 and 5 mg/day.</p><p class="bulletIndent1"><span class="glyph">●</span>1 mg/day every three to four weeks at <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> doses from 5 mg/day down.</p><p></p><p>Slower tapers may be appropriate in patients who have previously relapsed during a taper. (See  <a class="medical medical_review" href="/d/html/7983.html" rel="external">"Glucocorticoid withdrawal", section on 'Recommended tapering regimen'</a>.)</p><p>Some patients suffer recurrent relapses (cough, dyspnea, or chest pain) during tapering but are clinically stable on <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>. Since toxicities from systemic glucocorticoids are cumulative and there is no clear-cut safe dose, patients requiring long-term treatment with steroids are candidates for glucocorticoid-sparing therapies [<a href="#rid47">47</a>]. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p class="headingAnchor" id="H3972467251"><span class="h2">Efficacy of glucocorticoids</span><span class="headingEndMark"> — </span>The balance of evidence suggests that oral glucocorticoids improve respiratory symptoms and radiographic abnormalities, although not necessarily PFTs [<a href="#rid27">27,38,45,51,52</a>]. The results of individual trials have been variable, probably due to variations in patient populations, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> dose, and duration of therapy [<a href="#rid38">38,53,54</a>].</p><p>The best evidence in favor of glucocorticoid therapy for pulmonary sarcoidosis comes from systematic reviews that found improvement in radiographic findings after 3 to 24 months of treatment with a range of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> doses (4 to 40 mg) [<a href="#rid6">6,27,55</a>]. One analysis of five randomized trials assessing chest radiography found that oral glucocorticoid therapy decreased chest radiograph opacities compared with observation or placebo (risk ratio [RR] 1.46, 95% CI 1.01-2.09) [<a href="#rid27">27</a>]. A separate systematic review of 340 patients from three placebo-controlled trials demonstrated radiographic improvement in the treatment group (RR 1.35, 95% CI 1.11-1.64) and lower prevalence of radiographic deterioration (RR 0.39, 95% CI 0.18-0.87) [<a href="#rid6">6</a>].</p><p>Although many studies have not assessed patient-centered outcomes, oral glucocorticoids likely improve dyspnea and fatigue within several weeks of initiation [<a href="#rid41">41,45</a>].</p><p>In contrast, lung function tests have been assessed in several trials, but the timing, studies, and results have been variable and not easily grouped for meta-analysis [<a href="#rid27">27</a>]. At least two of the trials examined found no improvement in lung function [<a href="#rid27">27,28</a>]. DLCO was assessed in only two trials; one trial found no benefit and the other demonstrated a modest improvement among patients with stage II disease  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>) treated for 18 months but not at earlier interval assessments [<a href="#rid7">7,8,28</a>].</p><p>Assessing the benefit of glucocorticoid therapy for pulmonary sarcoidosis is limited not only by the paucity of clinical trial data but also by several additional challenges at the individual patient level [<a href="#rid27">27,55,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Many patients with sarcoidosis undergo spontaneous remission or have a benign clinical course (see <a class="local">'Long-term outcome'</a> below). The marked variability in presentation and clinical course makes it difficult to evaluate whether an apparent response to therapy reflects a treatment effect or the natural course of that patient's disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no easy way to globally assess disease activity or severity as symptoms may be discordant with results of PFTs and chest imaging. This makes it difficult to interpret the results of clinical studies or the response to therapy in an individual patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a concern that early administration of systemic glucocorticoid therapy may increase the likelihood that the patient will develop relapsing disease rather than a sustained remission [<a href="#rid57">57-59</a>].</p><p></p><p class="bulletIndent1">For example, in a prospective series of 215 patients with recent-onset sarcoidosis, only 8 percent of initially untreated patients required therapy after two years, whereas 47 percent of initially treated patients remained on therapy [<a href="#rid60">60</a>]. One explanation for this observation is that treatment limited the body's innate ability to clear the disease. However, a reasonable alternate explanation is that the patients, who were not randomly assigned to treatment groups, were selected for therapy based on subtle indications that they had more severe disease [<a href="#rid61">61</a>].</p><p></p><p>Data are very limited regarding the effect of oral glucocorticoids on long-term disease outcomes [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H2195032091"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>Numerous adverse effects are associated with chronic systemic glucocorticoid therapy  (<a class="graphic graphic_table graphicRef143142" href="/d/graphic/143142.html" rel="external">table 4</a>). For example, registry data suggest that patients with sarcoidosis treated with corticosteroids have a greater than twofold increase in the development of diabetes mellitus compared with matched patients without sarcoidosis (12.7 per 1000 versus 5.5 per 1000 person-years) [<a href="#rid63">63</a>]. Patients on more than 20 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or the equivalent should receive prophylaxis for the prevention of <em>Pneumocystis jirovecii</em> pneumonia. Additional information regarding the identification and prevention of glucocorticoid adverse effects can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids", section on 'Organ-based toxicity of systemic glucocorticoids'</a> and  <a class="medical medical_review" href="/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'</a>.)</p><p>Prevention of glucocorticoid-induced bone loss is a complicated issue in patients with sarcoidosis compared with other glucocorticoid-requiring diseases due to production of vitamin D by sarcoidosis granulomas and the risk of hypercalcemia and hypercalciuria with calcium supplementation. Monitoring of serum calcium, urine calcium, serum 25-hydroxyvitamin D (calcidiol), and serum 1,25-dihydroxyvitamin D (calcitriol) should be performed routinely in patients with sarcoidosis  (<a class="graphic graphic_table graphicRef67386" href="/d/graphic/67386.html" rel="external">table 5</a>). In patients without baseline hypercalcemia or hypercalciuria on oral glucocorticoids, we advise calcium (1000 to 1200 mg/day) and vitamin D (600 to 800 mg/day) intake through dietary sources  (<a class="graphic graphic_figure graphicRef79375" href="/d/graphic/79375.html" rel="external">figure 1</a>). If this cannot be achieved, oral supplementation should be followed by reassessment of calcium and/or vitamin D (calcidiol and calcitriol) within three months after initiation. (See  <a class="medical medical_review" href="/d/html/841.html" rel="external">"Hypercalcemia in granulomatous diseases", section on 'Sarcoidosis'</a> and  <a class="medical medical_review" href="/d/html/2023.html" rel="external">"Calcium and vitamin D supplementation in osteoporosis", section on 'Dietary sources'</a> and  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Calcium and vitamin D'</a> and  <a class="medical medical_review" href="/d/html/91259.html" rel="external">"Overview of extrapulmonary manifestations of sarcoidosis"</a>.)</p><p>All patients with pulmonary sarcoidosis receiving oral glucocorticoids should have their fracture risk formally assessed, and most patients will qualify for bone mineral density (BMD) assessment as well. In general, bisphosphonates are recommended for prevention of bone loss and fractures in postmenopausal females and males ≥50 years old who require systemic glucocorticoids ≥7.5 mg/day for longer than three months, have osteoporosis by BMD assessment, <strong>or</strong> are considered at high risk for bone fragility. Additional discussion regarding evaluation of and pharmacologic therapy for patients receiving glucocorticoids is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis", section on 'Evaluation'</a> and  <a class="medical medical_review" href="/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis", section on 'Candidates for pharmacologic therapy'</a>.)</p><p class="headingAnchor" id="H339274818"><span class="h1">PATIENTS WITH LIMITED TOLERANCE OF ORAL GLUCOCORTICOIDS</span><span class="headingEndMark"> — </span>A minority of patients with severe or progressive pulmonary sarcoidosis are unable to tolerate glucocorticoids. For these patients, a nonbiologic immunosuppressant, typically <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, is preferred to achieve disease control.</p><p class="headingAnchor" id="H270053888"><span class="h2">Patients with rapid progression</span><span class="headingEndMark"> — </span>For patients with rapid progression of disease when we initiate therapy, we prefer to use 20 mg of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> orally (based on patient acceptance and/or tolerance of short-term side effects) for four to six weeks while beginning an alternative agent because the alternative agents usually take some time to dose-adjust or achieve maximal effectiveness (or both). Subsequent maintenance and tapering of prednisone are individualized based on patient response to therapy and side effects from systemic glucocorticoids.</p><p class="headingAnchor" id="H3121706314"><span class="h2">Other patients</span><span class="headingEndMark"> — </span>Other patients can be initiated on an alternative regimen without glucocorticoid therapy. Nonbiologic agents in general require several months to achieve initial efficacy. If effective, therapy should preferably be maintained for one year to decrease the odds of relapse upon discontinuation. Most oral nonbiologic agents (<a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a>) are appropriate to taper slowly over three to six months while monitoring for signs of relapse.</p><p class="headingAnchor" id="H681013991"><span class="h3">Methotrexate therapy (preferred)</span><span class="headingEndMark"> — </span>For patients with severe or progressive pulmonary sarcoidosis who decline oral glucocorticoids or experience significant glucocorticoid side effects upon initiation of therapy, we suggest initial treatment with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> rather than observation alone or initiation of other alternative therapies. Methotrexate is the most used nonglucocorticoid agent for the treatment of patients with sarcoidosis [<a href="#rid42">42</a>]. It is an effective steroid-sparing agent [<a href="#rid64">64-67</a>] and in one trial prevented progression and relapses better than oral glucocorticoids when used as initial therapy [<a href="#rid68">68</a>]. It is contraindicated in pregnancy and in patients with nonsarcoidosis hepatic disease, and alcohol use should be minimized. Patient-reported side effects are less common than with oral glucocorticoids [<a href="#rid69">69</a>]. Pretreatment preparation, dosing, adverse effects, and efficacy of methotrexate in patients with sarcoidosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p class="headingAnchor" id="H223887879"><span class="h3">Alternative initial therapies</span><span class="headingEndMark"> — </span>There is no clear consensus on alternative nonbiologic options in those with contraindications or toxicity to <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> [<a href="#rid6">6,40</a>]. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> performed similarly to methotrexate in a small trial [<a href="#rid67">67</a>]; <a class="drug drug_general" data-topicid="10097" href="/d/drug information/10097.html" rel="external">leflunomide</a> has also demonstrated effectiveness in small cohorts [<a href="#rid70">70,71</a>]. Additional discussion of the use of these agents in the treatment of sarcoidosis, including dosing, adverse effects, and efficacy, may be found elsewhere. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Patients who progress on or cannot use methotrexate'</a>.)</p><p class="headingAnchor" id="H747619644"><span class="h1">ASSESSING RESPONSE TO THERAPY</span><span class="headingEndMark"> — </span>The optimal tools and timing for assessing the response to therapy in pulmonary sarcoidosis have not been well studied [<a href="#rid1">1</a>]. In the absence of a well-defined assessment tool, we use a combination of symptoms, physical examination, radiographic abnormalities, and pulmonary function tests (PFTs) to assess pulmonary disease burden. It is also important to concomitantly monitor patients with sarcoidosis for development of extrapulmonary disease. A general guideline and list of tests are provided in the table  (<a class="graphic graphic_table graphicRef67386" href="/d/graphic/67386.html" rel="external">table 5</a>). An approach to monitoring sarcoidosis is presented separately. (See  <a class="medical medical_review" href="/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis", section on 'Ongoing monitoring'</a>.)</p><p>Many experts believe that symptoms are the most important parameter to follow, although this approach depends on the reliability of the individual patient in perceiving and reporting symptoms. A difficult situation can arise when a patient experiences subjective improvement with therapy without objective changes. In this situation, a careful discussion about the relationship of symptoms and granulomatous inflammation may help inform the decision about whether to continue with potentially toxic therapy.</p><p>The PFTs that we follow at three- to six-month intervals (depending on disease course) are spirometry and diffusing capacity of the lung for carbon monoxide (DLCO). We reserve ambulatory oximetry for patients with moderate to severe dyspnea, poor exercise tolerance, and severe DLCO impairment.</p><p>A favorable response to therapy is defined by:</p><p class="bulletIndent1"><span class="glyph">●</span>A decrease in symptoms, especially dyspnea, cough, or fatigue.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A reduction in or clearing of radiographic abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased efficiency of ventilation or gas exchange (eg, improvement in spirometry, DLCO, or exercise oximetry).</p><p></p><p>Stabilization of radiographic abnormalities and lung function for prolonged periods of time (three to six months) should also be considered a positive response to treatment in patients who previously exhibited progressive pulmonary deterioration.</p><p>Patients who improve and remain stable for more than one year following cessation of therapy have a low rate of relapse [<a href="#rid48">48</a>].</p><p>Sarcoidosis granulomas produce angiotensin-converting enzyme (ACE), and serum ACE levels are elevated in 60 percent of patients with sarcoidosis [<a href="#rid1">1</a>]. However, following serum ACE levels has not been demonstrated to be useful in the management of sarcoidosis [<a href="#rid72">72,73</a>]. Additionally, ACE inhibitor therapy suppresses ACE levels [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H60533888"><span class="h1">RELAPSES AND ACUTE BRONCHITIC SYMPTOMS</span><span class="headingEndMark"> — </span>Relapses may occur during tapering of immunosuppression or after discontinuation of therapy. Clinically, relapses are characterized by two or more of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening bronchitic symptoms (dyspnea, cough, wheezing, and fatigue)</p><p class="bulletIndent1"><span class="glyph">●</span>A fall of 10 percent or more in forced vital capacity (FVC), total lung capacity (TLC), or diffusing capacity of the lung for carbon monoxide (DLCO)</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening of radiographic opacities</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased gas exchange at rest or with exercise</p><p></p><p>We use the following therapeutic approach for these relapses of disease activity:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients who relapse during a taper or after discontinuation of therapy</strong> – For these patients, therapy can be reinitiated. The dose of choice can range between the lowest prior effective antisarcoidosis dose up to the initial dose required for disease control, depending on the severity of the symptoms. Subsequent tapering of the same agent should be more gradual than the taper that resulted in a relapse. (See <a class="local">'Stopping glucocorticoid therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with acute bronchitic symptoms while on maintenance </strong><strong>prednisone</strong><strong> therapy</strong> – Patients frequently describe "flares" of pulmonary sarcoidosis, either after viral syndromes or without an obvious precipitant. The pathologic correlate of these "flares" is unknown, but given the usual rate of granuloma development, they are most likely nongranulomatous bronchitic episodes. In these patients, we suggest a treatment course of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg/day for two to three weeks followed by an immediate resumption of the prior effective therapeutic regimen. A retrospective study of 36 pulmonary sarcoidosis patients with acute exacerbations of bronchitic symptoms showed that treatment with the equivalent of prednisone 20 mg/day for approximately 21 days resulted in improvement of symptoms and return of lung function to baseline [<a href="#rid44">44</a>]. Following treatment, maintenance therapy can be continued at the prior stable dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>For patients with bronchitic symptoms while receiving maintenance therapy with alternative nonbiologic agents</strong> – For these patients, we suggest a two-week trial of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 20 mg followed by a rapid (one- to two-week) taper in those who can tolerate short-term and/or moderate-dose glucocorticoids. Otherwise, monitoring with close follow up is reasonable for milder exacerbations, and a dose increase in immunosuppression can be attempted in more severe cases. Frequent exacerbations should prompt consideration of alternative therapy. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Patients with disease refractory to the above agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Repeated relapses</strong> – Patients with pulmonary sarcoidosis who have frequent relapses despite this treatment approach may benefit from the addition or substitution of alternative immunosuppressive agents [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p></p><p class="headingAnchor" id="H806592626"><span class="h1">LONG-TERM OUTCOME</span><span class="headingEndMark"> — </span>It has been estimated that spontaneous remission occurs in approximately 60 to 80 percent of patients with radiographic stage I disease, 50 to 60 percent with stage II disease, and less than 30 percent in stage III disease  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>) [<a href="#rid19">19</a>]. The overall death rate from sarcoidosis is less than 5 percent [<a href="#rid1">1</a>].</p><p>Causes of death in sarcoidosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive pulmonary fibrosis and cor pulmonale. (See  <a class="medical medical_review" href="/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/8262.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Epidemiology, pathogenesis, and diagnostic evaluation in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hemorrhage from aspergillomas developing in damaged lung tissue. (See  <a class="medical medical_review" href="/d/html/2440.html" rel="external">"Chronic pulmonary aspergillosis: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Extrapulmonary sarcoidosis, including cardiac, neurologic, and hepatic disease.</p><p class="bulletIndent1"><span class="glyph">●</span>Nongranulomatous complications of sarcoidosis therapies, such as excess cardiovascular mortality and infections induced by complications of immunosuppressive therapy.</p><p></p><p>(See  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis"</a> and  <a class="medical medical_review" href="/d/html/4922.html" rel="external">"Clinical manifestations and diagnosis of cardiac sarcoidosis", section on 'Prevalence'</a>.)</p><p class="headingAnchor" id="H101849661"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116637.html" rel="external">"Society guideline links: Sarcoidosis"</a>.)</p><p class="headingAnchor" id="H1350366435"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15477.html" rel="external">"Patient education: Sarcoidosis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/4646.html" rel="external">"Patient education: Sarcoidosis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H4117695008"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing risk for progressive disease</strong> – Most pulmonary sarcoidosis does not require treatment, but progressive lung disease occurs in approximately 25 percent of patients. We assess disease severity by patient symptoms, radiographic involvement  (<a class="graphic graphic_table graphicRef56321" href="/d/graphic/56321.html" rel="external">table 1</a>), and pulmonary function testing (PFTs). (See <a class="local">'Introduction'</a> above and <a class="local">'Assessing disease severity and progression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients</strong> – For most asymptomatic patients, we suggest observation rather than initiating therapy with oral glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). We monitor symptoms and pulmonary function at three- to six-month intervals, with chest radiography every 6 to 12 months. However, for the subset of asymptomatic patients who present with severe disease, we suggest a trial of oral glucocorticoids (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Criteria for severe disease are discussed above. (See <a class="local">'Approach to asymptomatic patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic patients</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Those with mild lung involvement</strong> – For symptomatic patients with minimal or mild radiographic and pulmonary function changes, a therapeutic trial of low-dose <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (5 to 10 mg/day) may be appropriate  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). We often assess responsiveness with a moderate dose (20 mg/day) followed by a taper to low doses following the initial response. Administration of moderate- to high-dose inhaled glucocorticoids is a reasonable alternative approach. Most of these patients will undergo spontaneous remission, so observation is safe for patients who prefer to avoid pharmacologic therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Those with more severe and progressive disease</strong> – For symptomatic patients with pulmonary sarcoidosis who have severe lung involvement, worsening radiographic opacities, <strong>or</strong> increasing pulmonary function impairment, we suggest oral glucocorticoids rather than alternative therapies (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>)  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). We typically start <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> at 20 mg/day for at least four weeks and up to three months to allow for disease response. (See <a class="local">'Patients with more severe or progressive disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who cannot tolerate oral glucocorticoids</strong> – For patients who cannot tolerate oral glucocorticoids, we suggest initial therapy with a nonbiologic immunosuppressant for disease control, typically <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients with limited tolerance of oral glucocorticoids'</a> above and  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy", section on 'Patients who progress on or do not tolerate glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessing response to therapy</strong> – We monitor symptoms, physical examination, radiographic abnormalities, and PFTs at four- to six-week intervals during initial therapy and at three- to six-month intervals while on maintenance therapy  (<a class="graphic graphic_algorithm graphicRef141639" href="/d/graphic/141639.html" rel="external">algorithm 1</a>). (See <a class="local">'Assessing response to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapses and acute bronchitic symptoms</strong> – Relapses describe worsening of pulmonary disease during tapering of immunosuppression or after discontinuation of therapy. They are typically managed by increasing immunosuppressant therapy to the last effective dose. Acute bronchitic symptoms while on maintenance therapy may be treated with moderate-dose oral glucocorticoids (eg, 20 mg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>) for two to three weeks. (See <a class="local">'Relapses and acute bronchitic symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong> – For patients who are unable to tolerate the adverse effects of glucocorticoids, whose disease cannot be controlled on the equivalent of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> 10 mg or less, or who have evidence of disease progression despite a moderate dose of prednisone, an alternative immunosuppressive agent may be of benefit. (See  <a class="medical medical_review" href="/d/html/4325.html" rel="external">"Treatment of pulmonary sarcoidosis refractory to initial therapy"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153.</a></li><li><a class="nounderline abstract_t">Baughman RP, Grutters JC. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med 2015; 3:813.</a></li><li><a class="nounderline abstract_t">Wijsenbeek MS, Culver DA. Treatment of Sarcoidosis. Clin Chest Med 2015; 36:751.</a></li><li><a class="nounderline abstract_t">Gupta R, Judson MA, Baughman RP. Management of Advanced Pulmonary Sarcoidosis. Am J Respir Crit Care Med 2022; 205:495.</a></li><li><a class="nounderline abstract_t">Fernández-Ramón R, Gaitán-Valdizán JJ, González-Mazón I, et al. Systemic treatment in sarcoidosis: Experience over two decades. Eur J Intern Med 2023; 108:60.</a></li><li><a class="nounderline abstract_t">Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021; 58.</a></li><li><a class="nounderline abstract_t">Pietinalho A, Tukiainen P, Haahtela T, et al. Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group. Chest 1999; 116:424.</a></li><li><a class="nounderline abstract_t">Zaki MH, Lyons HA, Leilop L, Huang CT. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med 1987; 87:496.</a></li><li><a class="nounderline abstract_t">Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest 2018; 153:105.</a></li><li><a class="nounderline abstract_t">Walsh SL, Wells AU, Sverzellati N, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med 2014; 2:123.</a></li><li><a class="nounderline abstract_t">DeRemee RA. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest 1977; 71:388.</a></li><li><a class="nounderline abstract_t">Hunninghake GW, Gilbert S, Pueringer R, et al. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994; 149:893.</a></li><li><a class="nounderline abstract_t">Takada K, Ina Y, Noda M, et al. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993; 46:359.</a></li><li><a class="nounderline abstract_t">Harper LJ, Gerke AK, Wang XF, et al. Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis. Am J Respir Crit Care Med 2020; 201:955.</a></li><li><a class="nounderline abstract_t">Mirsaeidi M, Machado RF, Schraufnagel D, et al. Racial difference in sarcoidosis mortality in the United States. Chest 2015; 147:438.</a></li><li><a class="nounderline abstract_t">Tanizawa K, Handa T, Nagai S, et al. Lung function decline in sarcoidosis. Respir Investig 2022; 60:551.</a></li><li><a class="nounderline abstract_t">Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63 Suppl 5:v1.</a></li><li><a class="nounderline abstract_t">Malaisamy S, Dalal B, Bimenyuy C, Soubani AO. The clinical and radiologic features of nodular pulmonary sarcoidosis. Lung 2009; 187:9.</a></li><li><a class="nounderline abstract_t">Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336:1224.</a></li><li><a class="nounderline abstract_t">Michielsen HJ, Drent M, Peros-Golubicic T, De Vries J. Fatigue is associated with quality of life in sarcoidosis patients. Chest 2006; 130:989.</a></li><li><a class="nounderline abstract_t">Voortman M, Hendriks CMR, Elfferich MDP, et al. The Burden of Sarcoidosis Symptoms from a Patient Perspective. Lung 2019; 197:155.</a></li><li><a class="nounderline abstract_t">de Kleijn WP, De Vries J, Lower EE, et al. Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 2009; 15:499.</a></li><li><a class="nounderline abstract_t">Møller J, Hilberg O, Bendstrup E. Fatigue in Patients with Sarcoidosis in Denmark. Lung 2023; 201:103.</a></li><li><a class="nounderline abstract_t">Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994; 7:624.</a></li><li><a class="nounderline abstract_t">James DG, Carstairs LS, Trowell J, Sharma OP. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet 1967; 2:526.</a></li><li><a class="nounderline abstract_t">Culver DA, Ribeiro Neto ML, Moss BP, Willis MA. Neurosarcoidosis. Semin Respir Crit Care Med 2017; 38:499.</a></li><li><a class="nounderline abstract_t">Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; :CD001114.</a></li><li><a class="nounderline abstract_t">Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002; 287:1301.</a></li><li><a class="nounderline abstract_t">Selroos OB. Use of budesonide in the treatment of pulmonary sarcoidosis. Ann N Y Acad Sci 1986; 465:713.</a></li><li><a class="nounderline abstract_t">Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis. Eur Respir J 1995; 8:682.</a></li><li><a class="nounderline abstract_t">Zych D, Pawlicka L, Zielinski J. Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis. Sarcoidosis 1993; 10:56.</a></li><li><a class="nounderline abstract_t">Milman N, Graudal N, Grode G, Munch E. No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study. J Intern Med 1994; 236:285.</a></li><li><a class="nounderline abstract_t">Spiteri MA, Newman SP, Clarke SW, Poulter LW. Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis. Eur Respir J 1989; 2:218.</a></li><li><a class="nounderline abstract_t">Erkkilä S, Fröseth B, Hellström PE, et al. Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis. Sarcoidosis 1988; 5:106.</a></li><li><a class="nounderline abstract_t">du Bois RM, Greenhalgh PM, Southcott AM, et al. Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study. Eur Respir J 1999; 13:1345.</a></li><li><a class="nounderline abstract_t">Schutt AC, Bullington WM, Judson MA. Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med 2010; 104:717.</a></li><li><a class="nounderline abstract_t">Baughman RP, Iannuzzi MC, Lower EE, et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:198.</a></li><li><a class="nounderline abstract_t">du Bois RM. Corticosteroids in sarcoidosis: friend or foe? Eur Respir J 1994; 7:1203.</a></li><li><a class="nounderline abstract_t">Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29:533.</a></li><li><a class="nounderline abstract_t">Rahaghi FF, Baughman RP, Saketkoo LA, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev 2020; 29.</a></li><li><a class="nounderline abstract_t">Broos CE, Poell LHC, Looman CWN, et al. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respir Med 2018; 138S:S31.</a></li><li><a class="nounderline abstract_t">Cremers JP, Drent M, Bast A, et al. Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide. Curr Opin Pulm Med 2013; 19:545.</a></li><li><a class="nounderline abstract_t">Dhooria S, Sehgal IS, Agarwal R, et al. High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial). Eur Respir J 2023; 62.</a></li><li><a class="nounderline abstract_t">McKinzie BP, Bullington WM, Mazur JE, Judson MA. Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci 2010; 339:1.</a></li><li><a class="nounderline abstract_t">Israel HL, Fouts DW, Beggs RA. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis 1973; 107:609.</a></li><li><a class="nounderline abstract_t">Pietinalho A, Tukiainen P, Haahtela T, et al. Early treatment of stage II sarcoidosis improves 5-year pulmonary function. Chest 2002; 121:24.</a></li><li><a class="nounderline abstract_t">Khan NA, Donatelli CV, Tonelli AR, et al. Toxicity risk from glucocorticoids in sarcoidosis patients. Respir Med 2017; 132:9.</a></li><li><a class="nounderline abstract_t">DeRemee RA. Sarcoidosis. Mayo Clin Proc 1995; 70:177.</a></li><li><a class="nounderline abstract_t">Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med 2003; 2:311.</a></li><li><a class="nounderline abstract_t">Rizzato G, Montemurro L, Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15:52.</a></li><li><a class="nounderline abstract_t">Turner-Warwick M, McAllister W, Lawrence R, et al. Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management? Thorax 1986; 41:903.</a></li><li><a class="nounderline abstract_t">Sharma OP, Colp C, Williams MH Jr. Course of pulmonary sarcoidosis with and without corticosteriod therapy as determined by pulmonary function studies. Am J Med 1966; 41:541.</a></li><li><a class="nounderline abstract_t">Harkleroad LE, Young RL, Savage PJ, et al. Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest 1982; 82:84.</a></li><li><a class="nounderline abstract_t">Young RL, Harkleroad LE, Lordon RE, Weg JG. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med 1970; 73:207.</a></li><li><a class="nounderline abstract_t">Paramothayan S, Lasserson T. Treatments for pulmonary sarcoidosis. Respir Med 2008; 102:1.</a></li><li><a class="nounderline abstract_t">Reich JM. Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy. Chest 2002; 121:32.</a></li><li><a class="nounderline abstract_t">Izumi T . Are corticosteroids harmful to sarcoidosis? Sarcoidosis 1994; 11 Suppl 1:119.</a></li><li><a class="nounderline abstract_t">Israel HL, Gottlieb JE. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1995; 151:920.</a></li><li><a class="nounderline abstract_t">Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111:623.</a></li><li><a class="nounderline abstract_t">Baughman RP, Judson MA, Teirstein A, et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006; 99:307.</a></li><li><a class="nounderline abstract_t">Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.</a></li><li><a class="nounderline abstract_t">Paramothayan NS, Lasserson TJ, Jones P. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2010; :CD001114.</a></li><li><a class="nounderline abstract_t">Entrop JP, Kullberg S, Grunewald J, et al. Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids. ERJ Open Res 2021; 7.</a></li><li><a class="nounderline abstract_t">Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17:60.</a></li><li><a class="nounderline abstract_t">Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 1995; 155:846.</a></li><li><a class="nounderline abstract_t">Fang C, Zhang Q, Wang N, et al. Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study. Sarcoidosis Vasc Diffuse Lung Dis 2019; 36:217.</a></li><li><a class="nounderline abstract_t">Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate vs azathioprine in second-line therapy of sarcoidosis. Chest 2013; 144:805.</a></li><li><a class="nounderline abstract_t">Gavrysyuk V, Merenkova I, Dziublyk Y, et al. Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis. Diagnostics (Basel) 2021; 11.</a></li><li><a class="nounderline abstract_t">Kahlmann V, Moor CC, Veltkamp M, Wijsenbeek MS. Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population. Chron Respir Dis 2021; 18:14799731211031935.</a></li><li><a class="nounderline abstract_t">Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21:43.</a></li><li><a class="nounderline abstract_t">Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38:1145.</a></li><li><a class="nounderline abstract_t">Baughman RP, Lower EE. Treatment of Sarcoidosis. Clin Rev Allergy Immunol 2015; 49:79.</a></li><li><a class="nounderline abstract_t">Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41:1424.</a></li><li><a class="nounderline abstract_t">Krasowski MD, Savage J, Ehlers A, et al. Ordering of the Serum Angiotensin-Converting Enzyme Test in Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy: An Avoidable but Common Error. Chest 2015; 148:1447.</a></li></ol></div><div id="topicVersionRevision">Topic 4359 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18032765" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26204816" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26593147" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34813386" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of Advanced Pulmonary Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36446677" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Systemic treatment in sarcoidosis: Experience over two decades.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34140301" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ERS clinical practice guidelines on treatment of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10453872" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3478618" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728933" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictors of Mortality in Pulmonary Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503267" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/837754" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The present status of treatment of pulmonary sarcoidosis: a house divided.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8143052" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcome of the treatment for sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8483000" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31825646" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188873" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Racial difference in sarcoidosis mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35400618" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Lung function decline in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757459" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843518" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The clinical and radiologic features of nodular pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9110911" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17035429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Fatigue is associated with quality of life in sarcoidosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30778661" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Burden of Sarcoidosis Symptoms from a Patient Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458531" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fatigue in sarcoidosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36773043" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fatigue in Patients with Sarcoidosis in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8013622" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4166889" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Treatment of sarcoidosis. Report of a controlled therapeutic trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28750463" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Neurosarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846612" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Corticosteroids for pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11886322" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3014964" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of budesonide in the treatment of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7656936" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Dutch Study Group on Pulmonary Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8134718" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inhaled budesonide vs prednisone in the maintenance treatment of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077885" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : No effect of high-dose inhaled steroids in pulmonary sarcoidosis: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2525101" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inhaled corticosteroids can modulate the immunopathogenesis of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2852389" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Inhaled budesonide influences cellular and biochemical abnormalities in pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10445610" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized trial of inhaled fluticasone propionate in chronic stable pulmonary sarcoidosis: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20089389" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12405489" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Use of fluticasone in acute symptomatic pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7925895" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Corticosteroids in sarcoidosis: friend or foe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18539243" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Treatment of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32198218" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29137908" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23880702" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37690784" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996733" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4572567" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A controlled trial of prednisone treatment of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796428" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Early treatment of stage II sarcoidosis improves 5-year pulmonary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29229111" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Toxicity risk from glucocorticoids in sarcoidosis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7845043" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14719997" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pharmacotherapeutic management of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572002" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The late follow-up of chronic sarcoid patients previously treated with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3035736" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5923597" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Course of pulmonary sarcoidosis with and without corticosteriod therapy as determined by pulmonary function studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7044709" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5454257" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954027" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatments for pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796429" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mortality of intrathoracic sarcoidosis in referral vs population-based settings: influence of stage, ethnicity, and corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Are corticosteroids harmful to sarcoidosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7881695" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Outcome of the treatment for sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9118698" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16595563" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Presenting characteristics as predictors of duration of treatment in sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12672326" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Corticosteroids for pulmonary sarcoidosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34046487" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10746262" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7717793" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Prolonged use of methotrexate for sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32476957" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23538719" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Methotrexate vs azathioprine in second-line therapy of sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34359372" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34569301" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127974" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Leflunomide for chronic sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21565914" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25989728" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treatment of Sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23397302" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Established and experimental medical therapy of pulmonary sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26225637" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Ordering of the Serum Angiotensin-Converting Enzyme Test in Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy: An Avoidable but Common Error.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
